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1. INTRODUCTION {#jocd13294-sec-0006}
===============

There has been a rising trend in the number of noninvasive fat reduction procedures, including cryolipolysis and radiofrequency, reaching more than 375 000 cases in 2018.[1](#jocd13294-bib-0001){ref-type="ref"} These devices work by delivering either cold or heat to the tissue, thus damaging the membrane of the adipocytes. This results in the release of free fatty acids that induce activation of macrophages and other inflammatory mediators stimulating the lipolytic process.[2](#jocd13294-bib-0002){ref-type="ref"}, [3](#jocd13294-bib-0003){ref-type="ref"} As the lipid droplets are large compared with the macrophages, it takes time to break them down, digest them, and clear them from the body, thereby delaying the result of fat reduction procedures. Details regarding the science behind adipose tissue physiology have recently been published.[2](#jocd13294-bib-0002){ref-type="ref"}

A topical product (TransFORM Body Treatment \[TFB\] with TriHex Technology^®^, Alastin^®^ Skincare) showed enhanced contour and reduced skin laxity following cryolipolysis of the arms.[4](#jocd13294-bib-0004){ref-type="ref"} In that randomized, double‐blind pilot study, the TFB product was compared with a bland moisturizer lotion (Cetaphil^®^ Lotion, Galderma Laboratories). After 12 weeks, the subjects treated with the TFB product achieved greater reduction in arm contour and skin laxity than those treated with a bland moisturizer.

Based on these promising results, the following clinical study was designed to examine the effects of TFB product when applied following abdominal cryolipolysis or radiofrequency therapy.

2. MATERIALS AND METHODS {#jocd13294-sec-0007}
========================

2.1. Subjects {#jocd13294-sec-0008}
-------------

Eligible subjects were women between 25 and 55 years of age with clearly visible bilateral subcutaneous adipose tissue appearing as a distinct bulge of fat in the abdomen with soft, pliable tissue and sufficient volume for treatment on both sides. The enrolled subjects expressed their willingness to avoid starting a major diet or exercise program and to maintain a constant weight within 5% of the baseline measure. Subjects were recruited from the general population and within the clinical site database.

Exclusion criteria included prior fat reduction procedures or implants in or near the planned treatment area, previous surgery in the abdomen area, excessive laxity or any contra‐indication to device usage, such as existing diseases or drug use, pregnancy, lactation, or planned pregnancy during the study.

2.2. Procedures {#jocd13294-sec-0009}
---------------

Prior to the procedure, the planned treatment areas were traced and photographed to ensure that only the treated areas of the body were mapped on 3‐dimensional (3‐D) volumetric photographs. Subjects underwent abdominal cryolipolysis (CoolSculpting^®^ System, Allergan) or radiofrequency of the abdomen (Vanquish ME™, BTL). Subjects treated with cryolipolysis received up to four cycles during one treatment session. A 3‐minute manual massage was performed immediately following treatment. Subjects treated with radiotherapy received six treatment sessions approximately 1 week apart.

The topical products were provided in a randomized, double‐blind fashion with bottles labeled for use on the right or left side of the treated abdomen. Subjects were instructed to apply two to three full pumps of the product twice daily to the appropriate side of the abdomen as marked on the bottles. The product was applied after bathing or showering without manual massage, and the area was allowed to dry prior to wearing clothes. Subjects were instructed to wash their hands in between right and left side application.

Subjects were evaluated during the follow‐up visits at 4‐, 8‐ and 12‐weeks post treatment. At each visit, change in volume on each side of the abdomen was objectively measured using a volumetric 3‐D camera system (3‐D LifeViz^®^ Infinity system. QuantifiCare). The 3‐D system captured eight 360° body images, which were joined to produce "life‐like" 3‐D body images. The camera software compared volume and contour changes over time. Using the volume map, the changes were highlighted with blue to represent volume reduction and red to represent volume increase. Efforts were made to ensure that the subjects\' photographs were obtained at the same time of the day.

2.3. Statistical analysis {#jocd13294-sec-0010}
-------------------------

For each subject, the difference in fat volume reduction was computed by subtracting the volume reduction readings on the placebo side from the TFB side. The means and standard deviations of differences at weeks 4, 8, and 12 were then computed. Parametric (paired *t* test) and nonparametric tests (signed‐rank test) were used to determine whether the mean difference in abdominal volume at each follow‐up visit was statistically significant to ensure that the data analysis was robust, regardless of which statistical methods were used.

3. RESULTS {#jocd13294-sec-0011}
==========

Fifteen female subjects, Fitzpatrick Skin Types I‐V, were enrolled and treated with radiofrequency (n = 2) and cryolipolysis (n = 13). All subjects completed the study and remained within 5% of their baseline weight. Two subjects were excluded from analysis due to them not losing volume on either side of the treatment area throughout the course of the study (nonresponders to devices).

Treatment with TFB reduced the mean fat volume by 8.1 (SD 13.4) mL, 12.2 (SD 16.9) mL, and 24.0 (SD 27.1) mL more than that with placebo at weeks 4, 8, and 12, respectively. These reductions in fat volume of the treatment side were significant at weeks 8 and 12 (for each, *P* \< .05). The data are summarized in Table [1](#jocd13294-tbl-0001){ref-type="table"}.

###### 

Difference in fat volume reduction using the TransFORM Body Treatment with TriHex Technology® versus placebo

  N = 13 PATIENTS                          
  ----------------- -------------- ------- -------
  4                 −8.1 (13.4)    .0511   .0547
  8                 −12.2 (16.9)   .0238   .0425
  12                −24.0 (27.1)   .0078   .0078

Paired *t* test.

Signed‐rank test.

John Wiley & Sons, Ltd

Figure [1](#jocd13294-fig-0001){ref-type="fig"} shows that treatment with TFB resulted in continuous reduction in fat volume over time. Subjects\' volume loss compared with baseline for each visit/timepoint is listed in Table [2](#jocd13294-tbl-0002){ref-type="table"}. Using this table, Figure [2](#jocd13294-fig-0002){ref-type="fig"} displays the percentage of subjects with greater volume loss on either the TFB or the placebo side. Volumes within 10% of each other were noted as equivalent on both sides. 38% of subjects had a greater volume loss on the TFB side at week 4, 54% at week 8 and 77% at week 12.

![Change in abdominal fat volume. Treatment with TFB yielded greater reduction in fat volume than the bland moisturizer over time with varying magnitudes](JOCD-19-677-g001){#jocd13294-fig-0001}

###### 

Three‐dimensional volumetric assessment per subject

  Subject             Treatment        Week 4      Week 8      Week 12
  ------------------- ---------------- ----------- ----------- -----------
  1                   Radiofrequency   −53/−20     −40/−4      −6/+14
  2                   Radiofrequency   −13/−13     −50/−12     −110/−64
  3                   Cryolipolysis    −5/−2       −76/−77     −84/−60
  4                   Cryolipolysis    −74/−59     −62/−60     −62/−37
  5                   Cryolipolysis    −48/−52     −14/−21     −42/−52
  6                   Cryolipolysis    −14/−11     +4/+16      −4/+19
  7                   Cryolipolysis    +4/+4       −25/−12     −8/+1
  8                   Cryolipolysis    No change   No change   No change
  9                   Cryolipolysis    No change   No change   No change
  10                  Cryolipolysis    −12/−13     −98/−68     −58/−34
  11                  Cryolipolysis    −19/−16     −12/−23     −37/−40
  12                  Cryolipolysis    +43/+42     −26/−29     −162/−112
  13                  Cryolipolysis    −12/−12     −29/−29     +49/+27
  14                  Cryolipolysis    −64/−27     −31/−3      −43/+6
  15                  Cryolipolysis    −24/−7      −30/−9      −153/−76
  Total volume loss   −291/−186        −489/−331   −720/−408   

John Wiley & Sons, Ltd

![Percentage of subjects with a greater volume loss on the TransFORM body treatment side compared with placebo side. Subjects with volumes within 10% of each other are considered equivalent](JOCD-19-677-g002){#jocd13294-fig-0002}

Digital images representing several study subjects are shown in Figures [3](#jocd13294-fig-0003){ref-type="fig"}, [4](#jocd13294-fig-0004){ref-type="fig"}, [5](#jocd13294-fig-0005){ref-type="fig"}.

![One month post cryolipolysis of the lower abdomen: Accelerated volume reduction on the TransFORM body treatment with TriHex Technology^®^ side (Subjects\' Right Side)](JOCD-19-677-g003){#jocd13294-fig-0003}

![Two months post radiofrequency of the abdomen: Accelerated volume reduction on the TransFORM body treatment with TriHex Technology^®^ side (Subjects\' Left Side)](JOCD-19-677-g004){#jocd13294-fig-0004}

![Three months post cryolipolysis of the lower abdomen: Accelerated volume reduction on the TransFORM body treatment with TriHex Technology^®^ side (Subjects\' Right Side)](JOCD-19-677-g005){#jocd13294-fig-0005}

4. DISCUSSION {#jocd13294-sec-0012}
=============

Topical TFB resulted in increased volume loss, which was greater for the treatment side than that for placebo at weeks 4 (38%), 8 (54%), and 12 (77%), respectively, and statistically significant at weeks 8 (*P* = .0238) and 12 (*P* = .0078). There were no reported adverse events.

Nonsurgical fat reduction procedures using various devices continue to gain popularity as new technology emerges. The therapeutic basis for these devices is causing damage to fat cells, which are then gradually eliminated through apoptosis and lipid droplet dissolution.[2](#jocd13294-bib-0002){ref-type="ref"} Owing to the size of these lipid droplets, it is difficult for macrophages to digest and clear them from the body; however, lipid droplets are eventually removed by the process of autophagy.[2](#jocd13294-bib-0002){ref-type="ref"}

The topical TFB product was developed using active peptides that stimulate autophagy. Liposomal coating of the peptides ensures easy entry to the target area *via* hair follicles where they enter the dermal white adipose tissue *en route* to the subcutaneous fat.[2](#jocd13294-bib-0002){ref-type="ref"} The autophagy process facilitates the autodigestion of the extruded lipid droplets by "repackaging" the large lipid fragments into smaller digestible units that attract macrophages and encourage phagocytosis.[2](#jocd13294-bib-0002){ref-type="ref"} Furthermore, other peptides in the formulation stimulate elastin and collagen neogenesis, thus improving skin tone.

In a similar pilot study, this topical TFB product was assessed using a split arm design (TFB versus bland moisturizer) following cryolipolysis on the arms. The results showed significant improvements in contour and laxity on the TFB‐treated arms after 8 weeks with continuing improvements through week 24.[4](#jocd13294-bib-0004){ref-type="ref"} The current study demonstrated that similar results could be obtained when topical TFB was added to noninvasive abdominal fat reduction procedures. While the decrease in fat volume was significant after 8 and 12 weeks, additional decreases may occur with longer use.

In conclusion, nonsurgical fat reduction is a popular procedure for a variety of body areas, including abdominal contouring. The results of this study and those of a previous pilot study showed a significant improvement in adipose volume loss when topical TFB is added to the regimen.
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